Month: August 2021

FOSTER CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced financial results for the second quarter ended June 30, 2021 and provided a business update. “The public health community continues to affirm the need for vaccines that can offer broader protection to prevent pneumococcal disease and, importantly, reach an expanded population including adults aged 50 and older as well as those at higher risk due to existing health conditions,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. “We are focused on making a significant contribution to fulfill this need with VAX-24,...

-Management to Host Conference Call on August 12 at 8am ET-Patient Enrollment in the ATTACK Phase 3 Registrational Trial Completed; Top-Line Data Readout Expected Early Fourth Quarter 2021 SUL-DUR Launch Planning Progresses with Appointment of Anna Diaz Triola as Chief Commercial Officer Data On SUL-DUR and ETX0462 Presented at World Microbe Forum $20 Million Private Placement Transaction Completed with InnovivaWALTHAM, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today financial results for the second quarter 2021 and issued a business update for the quarter and recent weeks. “During our second quarter and in recent weeks we continued to build upon the...

– Announces First Patients with Solid Tumors Dosed with Oral Fadraciclib –– Additional Phase 1/2 Trials for Fadraciclib and CYC140 Expected to Follow –– Cash Runway to Early 2023 –– Conference Call Scheduled August 11, 2021 at 4:30 p.m. ET – BERKELEY HEIGHTS, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the second quarter 2021. The quarter’s business highlights included an update on the Company’s progress with fadraciclib and CYC140, Cyclacel’s novel CDK2/9 and PLK1 inhibitors, respectively. “After announcing In July that the first patient...

Resonant-Designed RF Filter Shipment Volumes Grew a Record 450% Year-Over-Year; IP Portfolio Expands to over 375 Filed or Issued Patents AUSTIN, Texas, Aug. 11, 2021 (GLOBE NEWSWIRE) — Resonant Inc. (NASDAQ: RESN), a provider of radio frequency (RF) filter solutions developed on a robust intellectual property platform, designed to connect People and Things, today provided financial results for the second quarter ended June 30, 2021. Management Commentary “The second quarter of 2021 was marked by accelerating customer shipments of a record 17.5 million RF filters, continued advancements in our XBAR® RF filter technology to unlock next-generation networks and financial results in-line with previously issued guidance,” said George B. Holmes, Chairman and CEO of Resonant. “We continue to receive validation from industry leaders that...

Completed investigational new drug (“IND”) enabling studies for lead program, BMF-219, an irreversibly binding menin inhibitor. On track to complete IND submission for Phase I/II study of BMF-219 as treatment for patients with menin-dependent acute myeloid leukemia (“AML”) and acute lymphocytic leukemia (“ALL”) during the second half of this year Continued to advance ongoing preclinical studies of BMF-219 in a number of menin-dependent liquid and solid tumors, including Diffuse Large B Cell Lymphoma (“DLBCL”), to expand potential impact of novel drug    Initiated pathway validation studies in type 2 diabetes Continued to expand team and laboratory facilities to support long-term growth and clinical and preclinical development plans Strengthened Board of Directors with appointment of Sumita Ray, J.D., Chief Legal and Administrative Officer...

Continued Progress on COVID-19 and Immuno-Oncology Programs ATLANTA, GA, Aug. 11, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers, today announced its financial results for the quarter ended June 30, 2021. GeoVax’s management will host a live conference call and webcast at 4:30 p.m. Eastern Standard Time on Wednesday, August 11 to discuss financial results and provide a general business update. Details are provided below.   2021 YTD Highlights and Development Program Status Update COVID-19 Vaccine – GeoVax’s SARS-CoV-2 (COVID-19) vaccine is based on its GV-MVA-VLPTM technology, which enables insertion of multiple antigen fragments, potentially allowing for broad-spectrum virus prevention. Unlike...

Conference Call to Begin Today at 5:00 PM ET2Q 2021 Total Revenues of $23.3 million; +54% vs. 2Q 2020 2Q 2021 Afrezza Net Revenue of $10.0 million; +43% vs. 2Q 2020 $201.4 million of Cash, Cash Equivalents and Investments at June 30, 2021WESTLAKE VILLAGE, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq:MNKD) today reported financial results for the quarter and six months ended June 30, 2021. “I am really proud of how our team has executed so far in 2021 supporting the growth of Afrezza and preparing for the potential commercial launch of Tyvaso DPI,” said Michael Castagna, Chief Executive Officer of MannKind Corporation. “With the issuance of the convertible debt in the first quarter and the pay-down and restructuring of our legacy debt in the second quarter, we have a stronger balance sheet with lower...

Record Revenue of $744 million in the Second Quarter, up 13% Year-over-Year Core Revenue Grew 17% to $698 million Net loss of $(37) million, or $(0.18) per diluted share Non-GAAP Earnings Per Share Grew 14% Year-over-Year to $0.24 Quarterly Cash Flow From Operating Activities of $106 millionSAN ANTONIO, Aug. 11, 2021 (GLOBE NEWSWIRE) — Rackspace Technology, Inc. (Nasdaq: RXT), a leading end-to-end multicloud technology solutions company, today announced results for its second quarter ended June 30, 2021. Kevin Jones, Chief Executive Officer, commented, “Our second quarter financial results were solid, with double-digit revenue growth and strong operating profit margins. In addition, our working capital and cash management transformation programs have driven excellent results with more than $100 million of operating cash flow...

CALGARY, Alberta, Aug. 11, 2021 (GLOBE NEWSWIRE) — Birchcliff Energy Ltd. (“Birchcliff” or the “Corporation”) (TSX: BIR) is proud to announce its financial and operational results for the three and six months ended June 30, 2021. “Birchcliff had an excellent second quarter in 2021, with solid average production of 75,265 boe/d which resulted in $90.2 million of adjusted funds flow(1), a 315% increase from Q2 2020. Our average production in July exceeded 85,000 boe/d(2) based on field estimates and we are on track to meet our second half production guidance of 84,000 to 86,000 boe/d and our annual average production guidance of 79,000 to 81,000 boe/d. The performance of our new wells and the current strength we are seeing in oil and natural gas prices positions us for a very strong second half in 2021, with significant anticipated...